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The International Association for the Study of Lung Cancer Retro-
spective Staging Project culminated in a series of recommendations
to the International Union Against Cancer and to the American Joint
Committee on Cancer regarding the seventh edition of the tumor,
node, metastasis (TNM) classification for lung cancer. The Interna-
tional Staging Committee of the International Association for the
Study of Lung Cancer now issues this call for participation in the
Prospective Project designed to assess the validity of each compo-
nent of T, N, and M, and other factors relevant to lung cancer staging
and prognosis. In the Retrospective Project, the original data acqui-
sition was typically motivated by interests other than staging. In
contrast, the Prospective Project offers online data entry. Alterna-
tively, participants may transfer existing data, provided core objec-
tives are addressed. Cancer Research and Biostatistics will coordi-
nate data management and analysis. The study population is newly
diagnosed lung cancer patients. Data elements include patient char-
acteristics, baseline laboratory values, first-line treatment, TNM plus
supporting evidence, and survival. Pretreatment TNM will be col-
lected for all cases; postsurgical TNM, if resection is attempted. T
descriptors include size and degree of tumor extension, with further
description of extent of visceral pleural invasion, venous invasion,
carcinomatous lymphangitis, and pleural lavage cytology. M de-
scriptors characterize the newly proposed M1a category and sites of
distant metastases. Nodal station involvement is described by means
of a newly proposed nodal map, facilitating international participa-
tion, and allowing further investigation of nodal zones. Successful
collection and analysis of these data can be expected to yield
unprecedented improvements in the utility and validity of lung
cancer staging.
Key Words: IASLC Staging Committee, TNM classification of
lung cancer, Lung cancer staging, International database.
(J Thorac Oncol. 2009;4: 679–683)
The objectives of the Lung Cancer Staging Project of theInternational Association for the Study of Lung Cancer
(IASLC)1 have been achieved with the submission of recom-
mendations for the seventh edition of the tumor, node, me-
tastasis (TNM) classification for lung cancer to the Interna-
tional Union Against Cancer and to the American Joint
Committee on Cancer. These core recommendations and the
methodology used in the analysis of the retrospective data-
base have been published in this Journal,2–6 as well as
additional publications on small cell lung cancer, carcinoid
tumors, and prognostic factors.7–9
The limitations of the analysis of the retrospective
database derive from the fact that most databases that con-
tributed cases to the international database were not designed
to study the TNM classification of lung cancer. The most
important consequence was that although the clinical or
pathologic T status was recorded in most of the databases,
few included the finer details, such as the specific anatomic
sites of tumor extension. For this reason, most of the descrip-
tors that define T3 and T4 tumors could not be validated in
this retrospective study.2 The same is true for the potential
subdivision of the N1 and N2 nodal spread based on the
number of involved nodes or nodal stations,3 and for the
differences in the various forms of M1 disease.4
In addition, subtle differences between nodal maps
used in different parts of the world—e.g., the Mountain and
Dresler10 modification to the American Thoracic Society map
and the Naruke-Japan Lung Cancer Society map—11,12 com-
plicated previous attempts to analyze international data on
nodal involvement.
OBJECTIVES OF THE PROSPECTIVE PROJECT
To overcome the limitations of the Retrospective
Project, the International Staging Committee (ISC) of the
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IASLC is proposing a Prospective Project with the general
objective to refine future editions of the TNM classification
for lung cancer. This would imply the validation of all T-, N-,
and M descriptors, with special attention to those that could
not be validated with the analysis of the retrospective data-
base, and the validation of descriptors that are not included in
the present TNM classification. The specific primary objec-
tives for each T, N, and M component, as well as for other
factors, are outlined in Table 1.
These objectives would be achieved by collecting a
large prospective international database. This would, as far as
possible, correct the geographical omissions and dispropor-
tionate spread of treatment modalities, which were inevitable
in the retrospective data base, and would include both non-
small and small cell bronchogenic carcinomas at the time of
the initial diagnosis. In addition, at a recent IASLC workshop
in London, there was international support for the inclusion
of specific neuroendocrine subsets into the prospective data
set.13 Pleural mesothelioma is to be covered in a separate data
set at a later point.
DATA ELEMENTS
Based on the experience of the Retrospective Project,
the ISC has defined the data required to address the objectives
of the Prospective Project. Baseline data to be captured, at the
time a decision is made as to first-line treatment of newly
diagnosed lung cancer confirmed by histology or cytology,
include patient characteristics, baseline laboratory values,
treatment modalities, TNM stage, and all supporting evi-
dence. Beyond that, all patients will be followed for survival.
The complete set of data elements can be viewed online
(http://www.iaslc.org/staging-project.asp).
Patient characteristics include birth date, race, sex,
smoking history (never versus former versus current smoker),
years since quitting, years smoked, weight loss in previous 6
months, performance status, height, weight, and the specific
comorbid factors needed to calculate the Colinet score for
each patient: tobacco consumption, renal insufficiency, respi-
ratory comorbidity, cardiovascular comorbidity, neoplastic
comorbidity, and alcoholism.
Disease diagnosis descriptors include the date of clin-
ical trial entry (if applicable), method of disease detection,
whether diagnosis was based on cytology and/or histology
and the dates of each, location of the primary, degree of
tumor differentiation, and histologic type. For small cell lung
cancer, the presence of paraneoplastic syndrome, such as the
syndrome of inappropriate secretion of antidiuretic hormone
or ectopic adrenocorticotrophic hormone, and myasthenic
syndrome, will also be collected.
Baseline laboratory parameters include lactate dehy-
drogenase, hemoglobin, calcium, alkaline phosphatase, so-
dium, white cell count, neutrophil count, platelet count,
and albumin, including the upper and lower limits of
normal for each laboratory. Other prognostic factors of
interest include the maximum standard uptake value for the
primary tumor as well as for the nodes and pulmonary
function test results of forced vital capacity and forced
expiratory volume in 1 second.
TNM will be applied universally to nonsmall cell, small
cell, and neuroendocrine lung tumors, in accordance in the
seventh edition. The treatment section will first ask whether
there was an attempt to remove the primary tumor. If resec-
tion was not attempted, a single set of TNM will be collected
as representation of “evaluative” cTNM, and treatment infor-
mation will include whether or not chemotherapy and radia-
tion were given, with sites of radiation collected as well. The
basis for pretreatment T, N, and M will be documented in
terms of the use of history and physical examination, standard
radiology, magnetic resonance imaging, computerized to-
mography, positron emission tomography, bronchoscopy, or
more invasive surgical procedures not involving resection of
the primary tumor.
If resection of the primary was attempted, two sets of
TNM will be collected: pretreatment cTNM and postsurgical
TABLE 1. Study Objectives
Component Objective
T Assess the prognostic impact of tumor size.
Assess the classification capacity of each descriptor defining
T-status.
Study new conditions not included in the present T (e.g.,
differences between parietal pleura invasion and rib
invasion).
N Assess the prognostic impact of N-status.
Explore the prognostic impact of involved lymph node
“zones” within N1 and N2 categories.
Assess the prognostic impact of:
Nodal extent (single vs. multiple station involvement in
N1 and N2 locations),
Nodal size, i.e., the largest involved node within the
relevant N category, and
Individual nodes being involved in each nodal category.
Assess the prognostic impact of extracapsular extension.
Assess the prognostic impact of the N3 nodal location, i.e.,
contralateral mediastinum, ipsilateral or contralateral
supraclavicular fossa.
M Assess the prognostic impact of M-status, especially those
descriptors now included within the new category of
M1a proposed by the IASLC for the 7th edition.
Assess the prognostic impact of:
Single metastasis in a single organ
Multiple metastases in a single organ, and
Multiple metastases in several organs.
Other Assess the prognostic impact of histologic type and grade.
Assess the reliability of staging methods utilized in clinical
staging (for those tumors with pretreatment and
postsurgical classification).
Assess the prognostic impact of complete, incomplete, and
uncertain resections, according to the proposed
definitions of the IASLC.
Assess the prognostic impact of clinical factors, including
co-morbidity and pulmonary function tests.
Assess the prognostic impact of maximum standard uptake
value (SUV max), at the primary site and in any
positive nodal sites, for those patients with positron
emission tomography (PET) scans in the pretreatment
staging.
IASLC, International Association for the Study of Lung Cancer.
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pTNM. The date of the resection attempt, extent, and com-
pleteness of resection, according to the proposed complete-
ness of resection definitions of the IASLC,14 will be recorded,
with specification of sites of microscopic and macroscopic
residual disease. Timing of chemotherapy and radiation to the
primary tumor will be recorded relative to the resection
attempt (i.e., before versus after versus both).
Pretreatment T-, N-, and M descriptors will be collected
for all patients. Pretreatment T descriptors include clinical
features and the size and degree of tumor extension. The
presence of carcinomatous lymphangitis will also be de-
scribed in the area of the primary tumor, elsewhere within the
lobe of the primary, and involving other areas within the
ipsilateral and/or contralateral lung. Nodal assessment by
clinical or imaging studies will be recorded separately from
biopsy or cytology, according to the IASLC 2009 nodal
map.15 Pretreatment N descriptors include the individual
assessments of each nodal station as positive or negative for
tumor—or alternatively, of each nodal zone. The size and
location of the largest node will also be recorded.
A second, parallel set of postsurgical T-, N-, and M
descriptors will be collected for patients undergoing resec-
tion. The postsurgical T section will also record the extent of
visceral pleural invasion as proposed by Travis et al.,16
venous invasion, status of the fissures, presence of lymphatic
invasion, and pleural lavage cytology. The postsurgical M
section will indicate which, if any, of the M-status findings
changed as a result of the resection attempt. Optionally, the
number of nodes explored, number of positive nodes, and
presence of extracapsular involvement could be registered for
N3, N2, and N1 regions.
For patients with multiple tumor nodules considered to
be part of a single malignancy, extended data on the size,
histology, and distance of additional nodules from the main
mass will be collected, organized into three scenarios: the
same lobe as the primary, ipsilateral lobes other than the lobe
containing the primary tumor, and contralateral lobes.
For the uncommon patient with multiple synchronous
primary tumors, staging data from each primary will be
recorded separately.
Outcome variables to be collected will include the last
date of contact, vital status, and the date of death. Data
regarding the availability of tissue or results from molecular
studies will also be briefly surveyed to identify potential
resources for future collaborative research.
PROPERTY OF THE DATABASE AND
PUBLICATION POLICY
Institutions approved by the IASLC Staging Committee
for participation in this Prospective Project will preferably
enter the data from an inception cohort online using a secure,
web-based data entry; however, sites may alternatively peti-
tion the ISC to transfer data from an existing database.
Access to the online data entry system will be available
through the IASLC web site at http://www.iaslc.org, initially
to limited institutions in China, Spain, and the United States
which have agreed to pilot the system. Designed and admin-
istered by Cancer Research and Biostatistics (CRAB), the
system will incorporate extensive, between-field logic
checks, and provide a query system enabling communication
between CRAB and the institutions regarding the data. Trans-
fer of existing, external data will initially be limited to
selected partners from the retrospective project and centers
that facilitate correction of geographical gaps identified in the
retrospective data. Additional retrospective data may be re-
quired, however, stricter standards regarding data quality and
completeness will be enforced than in the previous study.
Each institution will retain full access and publishing rights to
its own data; however, the collective database will be the
property of the IASLC, and CRAB will be responsible for its
management, storage, and analysis.
Publications related to the objectives of the Prospective
Project of the IASLC Staging Committee (i.e., publications
providing recommendations for changes in the TNM classi-
fication) will be planned, researched, analyzed, and written
by the members of the respective Subcommittees, and will
follow the same authorship pattern used for the publications
on the retrospective data: Chairperson of the subcommittee,
members of the subcommittee in alphabetical order, Chair-
man of the Staging Committee, on behalf of the IASLC
Staging Committee, and participating institutions.
TIMELINE
Table 2 shows the timeline of the Prospective Project.
CALL FOR PARTICIPATION
The objectives of the Prospective Project of the ISC of
the IASLC are well defined, and the prospective dataset has
been designed to achieve the proposed objectives. The
project’s success will depend on both the extent of the
international participation and the quality of the data. Inter-
national representation is needed to ensure that the final
staging system applies to genetically diverse populations,
who may be subject to differing levels of investigations and
care. The Retrospective Project showed that quality of the
data is even more important than its size. It will, therefore, be
pivotal to collect complete data, especially when registering
the elements directly related to the pretreatment and postsur-
gical classification of lung cancer, the analysis of which is the
main objective of this project.
TABLE 2. Timeline of the Prospective Project
Year Activity
2009–2010 Data collection
2011–2012 Follow-up
2013 Data analysis
January 2014 Submission of recommendations to the UICC
and AJCC
January–July 2014 Publication of the recommendations in the Journal of
Thoracic Oncology
2016 Publication of 8th edition of the TNM classification by
the UICC and AJCC
UICC, International Union Against Cancer; AJCC, American Joint Committee on
Cancer; TNM, tumor, node, metastasis.
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Useful information not related to the anatomic exten-
sion of the disease can also be derived from the prospectively
registered data. The inclusion of the methods used in the
clinical staging will allow us to explore their reliability in
those patients undergoing lung resection, in whom the pre-
treatment and postsurgical classifications can be compared.
The IASLC has published consensus guidelines on clinical
staging based on the best evidence available in clinical
practice.17–19 With the information of the prospective data-
base, the IASLC would be able to review those guidelines
based on contemporary data specifically collected for the
purpose of staging analysis.
One of the objectives of the TNM classification is to
assign a prognosis based on the anatomic extent of the
disease. However, there are other factors that influence prog-
nosis of lung cancer that are not related to its anatomic
extension. Sex, age and comorbidity,20–22 biologic parame-
ters,23 and molecular and genetic factors are known to influ-
ence prognosis but have never been integrated into the TNM
classification. Information on comorbidity and basic blood
analyses is easily available from most patients. Because the
study of molecular and genetic factors is not standardized
or universally available, information on the accessibility of
these data would be collected, rather than the actual end
points. This could facilitate international collaborative
research among contributing centers. The maximum stan-
dard uptake value, which has shown prognostic rele-
vance,24 will also be registered in those patients undergo-
ing positron emission tomography scan in the pretreatment
staging of their tumors.
The prospective registration of all these anatomic and
nonanatomic parameters would allow us to address most of
the issues that are expected from the ISC of the IASLC.25
That said, the practical limitations of such an undertaking as
a worldwide tumor registry must be understood. At current
funding levels, the geographic expanse of the project and
diversity of languages does not afford the ability to perform
site audits or central pathology review or even to reimburse
the expense of data collection. Consequently, the ISC will not
be able to verify independently whether consecutive patients
have been enrolled or to detect errors in the interpretation of
source data. On the other hand, one can argue that these data
reflect “real world” experience, and an international classifi-
cation system must be reproducible in the diverse settings in
which it is applied. Finally, access to the online registry and
data retrieval is a service that has value to participants.
Automated consistency checks comparing the assigned T, N,
and M categories to the supportive data may actually
improve the implementation of staging guidelines over
time. We encourage the medical community involved in
the diagnosis and treatment of patients with lung cancer to
consider collecting data that are compatible with this data
set and to contribute these data to the Prospective Project
of the IASLC.
To obtain more information about the project, please
send an email to information@crab.org with “IASLC Staging
Project” in the subject line.
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